VGBR 04
Alternative Names: VGB-R04Latest Information Update: 12 Jul 2022
At a glance
- Originator Shanghai Vitalgen BioPharma
- Developer Chinese Academy of Medical Sciences; Shanghai Vitalgen BioPharma
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haemophilia B
Most Recent Events
- 06 Jul 2022 Clinical trials in Haemophilia B in China (IV), prior to July 2022 (Vitalgen BioPharma website, July 2022)
- 01 Jul 2022 Preclinical trials in Haemophilia B in China (IV), prior to July 2022 (Vitalgen BioPharma pipeline, July 2022)
- 01 Jul 2022 Vitalgen BioPharma plans a phase I/II trial for Haemophilia B in China (IV, Infusion) (NCT05441553)